Skip to content

Liberal use of oxygen in early stage of COVID-19 patients.

Early Liberal Oxygen Therapy in COVID-19: An open-labeled randomized control trial - OXYCOVID

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/029614
Enrollment
80
Registered
2020-12-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Early liberal oxygen therapy - PART I: Part I: Patients will be randomized to liberal oxygen supplementation where patient will be supplemented with oxygen with nasal prongs at a rate o

Sponsors

All India Institute of Medical Sciences Jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Part I: Patients >18 years of age diagnosed as COVID-19 positive by reverse transcriptase Polymerase Chain Reaction (RT PCR) and are having mild COVID-19 with cough or dyspnea or both with room air saturation is within normal limits ( > 94%). Part II: Patients >18 years of age diagnosed as COVID-19 positive by reverse transcriptase Polymerase Chain Reaction (RT PCR) and PaO2/FiO2 of 200-350 as assessed by arterial blood gas (ABG) analysis.

Exclusion criteria

Exclusion criteria: 1.Any patient requiring immediate intubation and ventilatory care 2.Hemodynamic instability BP 3.Elevated intracranial pressure 4.Altered sensorium or history of seizures 5.Any psychiatric comorbidity 6.Pregnancy 7.Patients at high risk of requiring CPR or defibrillation (known arrhythmias) 8.Known chronic cardiopulmonary diseases like Bronchial asthma (with history of wheeze or bronchodilator use), chronic obstructive pulmonary disease, interstitial lung disease (aassessed by Computed Tomography (CT) Chest), congestive heart failure (clinical assessment), and obstructive sleep apnea (assessed with Epworth Sleepiness scale). 9.Any recent acute condition like pulmonary embolism, acute coronary syndrome, deep vein thrombosis, intestinal obstruction or cerebrovascular accident.

Design outcomes

Primary

MeasureTime frame
Primary outcome â?? I: Time to becoming symptom free (cough, breathlessness. Primary outcome â?? II: Change in PaO2/FiO2 ratio in both groups will be compared. Timepoint: Primary outcome â?? I: Time to becoming symptom free (cough, breathlessness, assessed at 6th day. Primary outcome â?? II: Change in PaO2/FiO2 ratio in both groups will be compared at end of 6th day.

Secondary

MeasureTime frame
The following if occurring during the study duration are considered as outcomes/events and the patient will be followed up but trial will be ended for that patient if 1. Intubation/Mechanical Ventilation or Non-invasive ventilation. 2. Fall of PaO2/FiO2 to less than 200 with oxygen supplementation or rises to more than 350 without oxygen supplementation. 3. Death of any patient in study duration 4. Patient undergoing off oxygen trial and successfully completing it. Timepoint: day 6

Countries

India

Contacts

Public ContactDr Mahendra Kumar Garg

ALL INDIA INSTITUTE OF MEDICAL SCIENCES JODHPUR

mkgargs@gmail.com9089081353

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026